New 52-week analyses from the phase 3 SOL-1 trial suggest that the investigational intravitreal therapy AXPAXLI (OTX-TKI) may ...
Oraya Therapeutics Inc. announced today that leading ophthalmologists from three European countries presented patient results following one year after a single treatment with Oraya Therapy for wet age ...
W hen diagnosed with diabetic macular edema (DME) in 2017, Sarah Castaneda, 41, thought she would lose her eyesight completely. At least, that’s what her doctor told her would happen if she didn’t ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results